ArticleAnalytical chemistry2025
MAMSI: Integration of Multiassay Liquid Chromatography-Mass Spectrometry Metabolomics Data Using Multiview Machine Learning.
Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Liquid chromatography-mass spectrometry (LC-MS) is a commonly used analytical technique in untargeted metabolomics. However, the diverse chemical and physical properties of metabolites often require the use of several different analytical assays for broad metabolome coverage. Conventionally, each assay is analyzed separately, but this fails to capture interassay relationships, making multiassay biomarker discovery and data interpretation difficult. Here we propose a workflow to integrate multiassay metabolomics data, designed to enable biomarker discovery and elucidation of unknown metabolites. We employ a multiblock-partial least-squares model (MB-PLS) coupled with multiblock variable importance in projection to estimate the importance of predictors to the outcome variable. Then we cluster the selected predictors and compare them to groups defined by their structural properties based on retention time and mass-to-charge ratio. To demonstrate and evaluate the approach, we used three multiassay data sets predicting biological sex, Alzheimer's disease status, and blood bilirubin levels as the outcomes of interest. The MB-PLS models outperformed single-assay models in both classification and regression tasks, indicating that modeling interblock relationships enabled an improved estimate of phenotypic outcome. Additionally, the MB-PLS models shed valuable insight into each data block's contribution to the predicted outcome. Our workflow enabled us to determine a set of potential cross-assay biomarkers. Following putative annotation, the majority of these and their signs of association agreed with results previously reported in the literature. Our workflow has the potential to benefit the metabolomics community and beyond as it offers interpretable integrative analysis of multiassay LC-MS data and facilitates discovery of potential biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.